Home / Resource Library / Clinical implications of circulating tumor DNA in predicting the outcome of diffuse large B cell lymphoma patients receiving first‑line therapy
Clinical implications of circulating tumor DNA in predicting the outcome of diffuse large B cell lymphoma patients receiving first‑line therapy